Video

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Related Videos
Elizabeth Buchbinder, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Michael A. Postow, MD
Matthew P. Deek, MD
Related Content
The FDA has approved cosibelimab-ipdl for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
December 13th 2024

FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Cancer / Image credit: Cornflakesei – stock.adobe.com
December 2nd 2024

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

Blessy Mathew Jacob, MD; Ana Van Der Wall, MD; Vance M. Wright-Browne, MD
February 8th 2024

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

Douglas B. Johnson, MD, MSCI
November 22nd 2024

Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10